Ultragenyx Pharmaceutical Inc (RARE)
40.88
-0.30
(-0.74%)
USD |
NASDAQ |
May 10, 16:00
40.88
0.00 (0.00%)
After-Hours: 20:00
Ultragenyx Pharmaceutical Enterprise Value: 3.012B for May 9, 2024
Enterprise Value Chart
Historical Enterprise Value Data
Date | Value |
---|---|
May 09, 2024 | 3.012B |
May 08, 2024 | 3.043B |
May 07, 2024 | 3.076B |
May 06, 2024 | 3.163B |
May 03, 2024 | 3.142B |
May 02, 2024 | 3.179B |
May 01, 2024 | 3.188B |
April 30, 2024 | 3.124B |
April 29, 2024 | 3.247B |
April 26, 2024 | 3.266B |
April 25, 2024 | 3.233B |
April 24, 2024 | 3.269B |
April 23, 2024 | 3.338B |
April 22, 2024 | 3.219B |
April 19, 2024 | 3.109B |
April 18, 2024 | 3.193B |
April 17, 2024 | 3.254B |
April 16, 2024 | 3.104B |
April 15, 2024 | 3.151B |
April 12, 2024 | 3.494B |
April 11, 2024 | 3.801B |
April 10, 2024 | 3.876B |
April 09, 2024 | 3.789B |
April 08, 2024 | 3.762B |
April 05, 2024 | 3.763B |
Date | Value |
---|---|
April 04, 2024 | 3.500B |
April 03, 2024 | 3.500B |
April 02, 2024 | 3.459B |
April 01, 2024 | 3.491B |
March 31, 2024 | 3.468B |
March 28, 2024 | 3.267B |
March 27, 2024 | 3.278B |
March 26, 2024 | 3.166B |
March 25, 2024 | 3.162B |
March 22, 2024 | 3.198B |
March 21, 2024 | 3.264B |
March 20, 2024 | 3.293B |
March 19, 2024 | 3.293B |
March 18, 2024 | 3.259B |
March 15, 2024 | 3.323B |
March 14, 2024 | 3.264B |
March 13, 2024 | 3.420B |
March 12, 2024 | 3.347B |
March 11, 2024 | 3.417B |
March 08, 2024 | 3.583B |
March 07, 2024 | 3.610B |
March 06, 2024 | 3.643B |
March 05, 2024 | 3.661B |
March 04, 2024 | 3.812B |
March 01, 2024 | 3.843B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
1.201B
Minimum
Mar 16 2020
10.97B
Maximum
Dec 23 2020
3.694B
Average
3.124B
Median
Jun 07 2022
Enterprise Value Benchmarks
Corcept Therapeutics Inc | 2.361B |
Madrigal Pharmaceuticals Inc | 3.472B |
Sarepta Therapeutics Inc | 12.35B |
FibroGen Inc | 56.95M |
Rocket Pharmaceuticals Inc | 1.789B |
Enterprise Value Related Metrics
Net Income (Quarterly) | -170.68M |
Revenue (Quarterly) | 108.83M |
Total Expenses (Quarterly) | 274.18M |
EPS Diluted (Quarterly) | -2.03 |
Gross Profit Margin (Quarterly) | 83.89% |
Profit Margin (Quarterly) | -156.8% |
Earnings Yield | -19.64% |
Normalized Earnings Yield | -19.73 |